Dengue Testing Market Size & Trends
The global market for dengue testing was estimated at USD 612.53 million in 2024 and is expected to grow at a CAGR of 5.22% from 2025 to 2030, driven by escalating dengue outbreaks, technological advancements, and increased public health initiatives. The 2024 dengue epidemic in Latin America and the Caribbean, with over 13 million suspected cases and more than 8,000 deaths, demonstrates the importance of developing effective diagnostic solutions.
Key Highlights
- Asia Pacific dominated the market and accounted for the largest revenue share of about 31.57% in 2024.
- The dengue testing market in Japan is experiencing significant growth driven by government-funded surveillance programs and the deployment of RT-PCR and automated ELISA in public health labs.
- By product, the ELISA-based tests segment accounted for the largest market share of 44.94% in 2024.
- In terms of service, the centralized service segment led the market with a 59.93% share in 2024.
- By end-use, the clinical labs segment dominated the market with a revenue share of 44.16% in 2024.
In response, companies such as Abbott Laboratories and Roche Diagnostics have launched quick tests and advanced PCR tests to help detect and manage dengue infections earlier. These developments improve patient outcomes and contribute to controlling the spread of the disease.
Accurate diagnostics are central to managing dengue outbreaks effectively. Among the most widely used methods is the enzyme-linked immunosorbent assay (ELISA), which detects anti-DENV IgM/IgG antibodies and the NS1 antigen and can differentiate between all four dengue virus serotypes. ELISA remains the gold standard in clinical laboratories with the necessary equipment and skilled personnel. Meanwhile, innovations are expanding access to diagnostics beyond traditional settings. A prime example is the 2025 launch of the AccoDengue Home Test by AccoBiotech Sdn. Bhd. in Malaysia-a user-friendly, affordable rapid diagnostic kit that detects NS1 antigens and enables early detection at the household level, which is particularly beneficial in low-resource environments.
In addition to serological testing, molecular diagnostics are rapidly advancing and offering powerful new tools for early and precise detection. One such innovation is the CDC’s DENV-1-4 rRT-PCR assay, approved by the USFDA, which identifies dengue virus RNA during the initial seven days of infection. In 2025, researchers at the Institute for Global Health and Infectious Diseases unveiled a breakthrough blood test that can simultaneously detect both dengue and Zika viruses-critical for improving disease surveillance and guiding vaccine development. Another recent advancement is the anti-NS2BNS3pro antibody-based indirect ELISA, which has demonstrated strong diagnostic performance, with a sensitivity of 87% and solid specificity, providing additional options for case confirmation.
Technological innovations are also expanding the reach of dengue testing through point-of-care testing (POCT) devices, which offer fast, reliable results in decentralized settings. These tools are particularly valuable in low- and middle-income countries where access to centralized labs is limited. For example, Mylab Discovery Solutions has introduced a multiplex RT-PCR test kit capable of detecting several pathogens, including dengue, making it easier for clinicians to identify co-infections and implement timely treatment. This kind of innovation ensures faster diagnosis and contributes significantly to breaking the chain of transmission during outbreaks.
Moreover, robust government initiatives are accelerating the growth of the dengue testing market. Programs like India’s National Vector Borne Disease Control Program (NVBDCP) aim to raise awareness and expand diagnostic networks, thereby strengthening outbreak preparedness and surveillance. Similarly, targeted public health campaigns across Latin America are intensifying early detection efforts, emphasizing timely diagnosis as a core strategy for disease control. These interventions are not only saving lives but are also generating increased demand for reliable, scalable, and accessible diagnostic tools-solidifying diagnostics as a critical pillar in the global fight against dengue.
Report Coverage & Deliverables
The PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Market Concentration & Characteristics
The industry is marked by high innovation, particularly in rapid testing and molecular diagnostics. Technologies like RT-PCR, CRISPR-based assays, and home-based NS1 antigen kits are transforming early detection and outbreak management. Startups and research institutions are increasingly focusing on developing multiplex assays that can distinguish dengue from similar infections like Zika and chikungunya, making innovation a key competitive differentiator in the market.
Mergers and acquisitions are gaining traction in the dengue testing sector, with larger diagnostic firms acquiring smaller innovators to access proprietary technology and expand product portfolios. Recent examples include regional partnerships in Asia and Latin America, where companies are consolidating to streamline production and distribution. These M&A activities are driven by the rising market demand and the urgency to scale up affordable, rapid diagnostic tools in high-burden areas.
Regulations have a significant influence on market dynamics, affecting product approval timelines and commercialization. Regulatory bodies like the FDA, EMA, and WHO require stringent clinical validations for dengue tests, especially those targeting multiple serotypes. While such validation ensures product quality and safety, it can also delay market entry. However, emergency use authorizations during outbreaks have sometimes expedited the deployment of new diagnostic solutions, especially in resource-limited countries.
Product expansion in dengue testing includes the development of next-generation kits capable of detecting multiple arboviruses simultaneously. Companies are also introducing self-testing kits, mobile-integrated diagnostic tools, and more sensitive assays. This broadening of product lines caters to diverse settings, from centralized labs to remote clinics. As demand grows in urban and rural areas alike, product diversification is essential to meet varying diagnostic needs across healthcare ecosystems.
The industry is rapidly expanding across Asia-Pacific, Latin America, and parts of Africa due to high disease prevalence. Companies are strategically entering these regions through local partnerships, government collaborations, and regional distribution hubs. Additionally, North America and Europe are seeing increased product availability due to travel-related dengue cases. Regional expansion ensures wider access to diagnostics, bolsters outbreak response, and contributes to global dengue surveillance efforts.
Product Insights
The ELISA-based tests made up the biggest part of the market at 44.94% in 2024 because they are very accurate and can find both dengue antigens (NS1) and antibodies (IgM and IgG). These tests are particularly valuable in the early and late phases of infection, offering flexible diagnostic windows. In 2024, the global burden of dengue surged dramatically, leading to greater demand for accurate lab-based diagnostics. Companies like Abbott and Bio-Rad have strengthened their ELISA test offerings, introducing more rapid, multi-serotype detection kits. Furthermore, support from governments and international health agencies for centralized disease monitoring is boosting the use of ELISA as a core method for large-scale dengue surveillance.
The lateral flow immunoassay segment is projected to register the fastest CAGR during the forecast period due to its ease of use, rapid results, and minimal infrastructure requirements. LFIAs are particularly well-suited for point-of-care testing in remote and resource-limited settings, where laboratory access is restricted. In 2024, the dengue surge across Latin America and Southeast Asia underscored the urgency for quick diagnostics, and LFIA kits like SD BIOLINE Dengue Duo (by Abbott) and Panbio Dengue Rapid Tests gained significant traction. These tests detect NS1 antigen and IgM/IgG antibodies in under 20 minutes, enabling early identification and timely intervention. The affordability, portability, and growing government procurement of LFIA kits for outbreak response further fuel this segment’s expansion, making it vital in community-based dengue surveillance and control strategies.
Service Type Insights
The centralized service segment led the market with a 59.93% share in 2024, driven by the increasing demand for accurate and comprehensive testing solutions. Centralized laboratories, primarily located in hospitals and diagnostic centers, offer advanced diagnostic capabilities, including ELISA and RT-PCR tests, which are essential for confirming dengue infections. Government initiatives and investments in healthcare infrastructure further bolster this segment, enhancing laboratory capacities and accessibility. As dengue continues to pose a significant public health challenge, the centralized service segment is poised to play a pivotal role in disease management and control.
The POC service segment is projected to register the fastest CAGR during the forecast period, as healthcare systems prioritize rapid, on-site testing to combat seasonal outbreaks. Innovations such as Abbott’s SD BIOLINE Dengue Duo deliver NS1 antigen and IgM/IgG results in under 20 minutes,ling same-visit clinical decisions. Additionally, mobile-enabled POC platformstate real-time data transmission to public health dashboards, improving outbreak surveillance. Government procurement programs in endemic regions are also scaling POC deployment in remote clinics. Over the coming decade, we expect the POC service segment to surpass traditional laboratory services in dengue testing.
End-use Insights
The clinical labs segment dominated the market with a revenue share of 44.16% in 2024. Growth is driven by increased investments in laboratory automation, high-throughput ELISA,nd RT-PCR platforms,ling same-day turnaround. Major players such as LabCorp and Quest Diagnostics in North America have integratedue RT-PCR into their infectious disease panels, while networks of private labs in India and Brazil offer multiplex testing during peak seasons. Additionally, public health initiatives are consolidating surveillance testing in regional reference labs, further increasing test volumes.
Over the forecast period, we expect the government suppliers segment to grow at the fastest rate. Rising consumer demand for convenient, at-home NS1 antigen and IgM/IgG rapid tests underpins this growth. Recent studies show that dengue NS1 rapid immunochromatographic assays can be easily turned into self-test kits, and people from different backgrounds were able to successfully use the AccoDengue Home Test in a home setting. Commercial products, such as the R-test Dengue NS11 Ag Self-Test, provide 100% sensitivity and 99% specificity, allowing for early detection without the need for laboratory visits. With digital instruction modules (QR-linked videos) and mobile apps for result interpretation, home healthcare is set to capture an increasing share of the dengue testing market.
Regional Insights
The North American dengue testing market is experiencing significant growth, driven by robust public health surveillance and the adoption of point-of-care testing. The U.S. and Canada lead investments in rapid NS1 antigen assays and multiplex PCR platforms. Increased travel-related case importation has spurred laboratory upgrades, while federal initiatives bolster decentralized testing in clinics and urgent care centers, ensuring timely outbreak response and patient management.
U.S. Dengue Testing Market Trends
The dengue testing market in the U.S. is fueled by growing numbers of dengue cases in travelers and proactive CDC testing guidelines. Clinical laboratories and POC centers are integrating NS1 antigen and ex- RT-PCR assays into routine infectious disease panels. Insurance coverage for dengue testing has improved access, while public health campaigns at borders and airports enhance early detection efforts, establishing the U.S. as the leading market.
Europe Dengue Testing Market Trends
The dengue testing market in Europe is driven by increased travel to and from dengue-endemic regions, prompting reference laboratories to scale up RT-PCR and ELISA capacities. National public health agencies in France, Spain, and Italy fund specialized tropical disease centers, ensuring timely confirmation of imported cases. Private travel clinics also offer rapid NS1 and antibody tests. Combined with rising clinician awarenesss and cross-border data sharing, these factors underpin the region’s growing reliancee on high-precision dengue testing.
Returning travelers and expatriates are driving the UK dengue testing market by encouraging NHS and private clinics to improve dengue screening. The guidelines from Public Health England recommend RT‑PCR for early infection and ELISA for serosurveys, boosting laboratory test volumes. Major diagnostic companies supplyE-marked NS1 rapid tests to both hospitals and travel health providers. Coupled with investments in centralized reference labs and digital result reporting, the UK is strengthening its capacity for rapid, accurate dengue diagnosis.
In Germany, the dengue testing market is expanding as university hospital networks adopt multiplex RT‑PCR panels and automated ELISA platforms. The Robert Koch Institute issues alerts for imported infections, driving labs to maintain dengue assays year-round. Strategic partnerships between German biotech firms and global manufacturers streamline kit distribution. Meanwhile, tropical medicine clinics in major cities offer rapid NS1 antigen tests, meeting the diagnostic needs of travelers and migrant populations returning from endemic areas.
Asia Pacific Dengue Testing Market Trends
Asia Pacific dominated the market and accounted for the largest revenue share of about 31.57% in 2024. The dengue testing market in the Asia Pacific region dominated the market, owing to endemic dengue transmission in India, Indonesia, and Thailand. National vector control programs (e.g., India’s NVBDCP) fund ELISAnd RT-PCR in regional labs, while community health centers deploy POC NS1 rapid tests. Public-private partnerships expand molecular testing capacity,acity, and smartphone-linked devices enable remote result reporting. Climate change, urbanization, and increased healthcare investment further catalyze market expansion across the region.
The Japan dengue testing market is experiencing significant growth driven by government-funded surveillance programsng RT-PCR and automated ELISA deployment in public health labs. Collaborative research between universities and biotech companies has led to multiplex assays that differentiate dengue from Zika and chikungunya. Travel clinics at major airports also offer rapid NS1 antigen tests. Combined with strong healthcare funding and digital health platforms, these elements drive steady expansion of dengue testing.
The dengue testing market in China is witnessing substantial growth. In China, periodic outbreaks in southern provinces havempted large-scale molecular testing initiatives led by provincial CDCs. Domestic manufacturers supply affordable ELISA and rapid test kits, while centralized labs incorporate dengue assays into broader arbovirus panels. Government investments in public health infrastructure and electronic reporting systems ensure high testing throughput. Additionally, collaborations with international diagnostic firms introduce advanced POC platforms, further boosting market capacity.
Latin America Dengue Testing Market Trends
The dengue testing market in Latin America is witnessing significant growth driven by frequent dengue epidemics in Brazil, Mexico, and Colombia. The Pan American Health Organization supports national labs in scaling up ELISA and RT‑PCR testing. Widespread procurement of NS1 rapid tests for community clinics enhances early detection. With more money for controlling disease-carrying insects and tracking outbreaks, there is a high need for tests, which strengthens the area's dependence on both central labs and point-of-care solutions.
The Brazil dengue testing market is expanding with federal programs by Fiocruz and the Ministry of Health driving ELISAnd RT-PCR capacity. Local production of NS1 antigen kits reduces costs, while field testing campaigns in rural areas employ POC devices. Integrating dengue testing into national epidemiological reporting ensures high sample volumes. Combined with frequent outbreaks and government procurement agreements, these factors solidify Brazil’s leading position in regional dengue testing.
Middle East & Africa Dengue Testing Market Trends
The dengue testing market in the Middle East and Africa (MEA) is witnessing rapid expansion, as sporadic outbreaks in the Middle East (e.g., Oman, Saudi Arabia) and increasing surveillance in Africa spur diagnostic adoption. WHO-led initiatives fund POC NS1 and antibody tests in remote clinics. Regional reference labs in South Africa and the Gulf invest in RT‑PCR platforms. Donor-funded programs enhance training and quality control, ensuring progressive uptake of both rapid and centralized testing services.
The dengue testing market in Saudi Arabia is witnessing substantial growth, driven by pilgrim health screening during Hajj, where mandatory dengue testing protocols utilize rapid NS1 and RT-PCR assays at entry points. The Ministry of Health’s investments in mobile POC labs support remote regions. Partnerships with global diagnostic firms ensure the availability of CE-marked kits. Coupled with epidemiological data integration into national health systems, these measures underpin a rapidly expanding dengue testing sector.
Key Dengue Testing Company Insights
Key players operating in the dengue testing market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.
Key Dengue Testing Companies
The following are the leading companies in the dengue testing market. These companies collectively hold the largest market share and dictate industry trends.
- Thermo Fisher Scientific Inc.
- Abbott
- F. Hoffmann-La Roche Ltd.
- InBios International, Inc.
- NovaTec Immundiagnostica GmbH
- Abnova Corporation
- PerkinElmer Inc. (Euroimmun AG)
- Certest Biotec
- DiaSorin S.p.A.
- Quest Diagnostics Incorporated
Recent Developments
-
In December 2024, bioMérieux announced that its BIOFIRE FILMARRAY Tropical Fever (TF) Panel received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA). This advanced PCR testing solution allows for quick and accurate detection of germs in patients with unknown fevers, including dengue, which helps doctors make better and faster treatment choices.
-
In June 2024, QIAGEN launched its new QIAcuity digital PCR tests for studying germs, which enhances research and monitoring of infectious diseases by including tests for all four types of the Dengue virus.
-
In August 2024, J Mitra & Company introduced the Dengue NS1 Antigen self-test kit, India's first home-use diagnostic tool for dengue. This kit enables individuals to conduct tests independently, providing results within 20 minutes with easy visual interpretation.
Dengue Testing Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 637.90 million |
|
Revenue forecast in 2030 |
USD 822.61 million |
|
Growth rate |
CAGR of 5.22% from 2025 to 2030 |
|
Base year for estimation |
2024 |
|
Historical data |
2018-2023 |
|
Forecast period |
2025-2030 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Product, service type, end-use, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; Mexico; UK; Germany; France; Spain; Italy; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait, |
|
Key companies profiled |
Thermo Fisher Scientific Inc.; Abbott; F. Hoffmann‑La Roche Ltd.; InBios International, Inc.; NovaTec Immundiagnostica GmbH; Abnova Corporation; PerkinElmer Inc. (Euroimmun AG); Certest Biotec; DiaSorin S.p.A.; Quest Diagnostics Incorporated |
|
Customization scope |
Free report customization (equivalent to up to 8 analysts' working days) with purchase. Changes or additions to the scope of the country, region, and segment are possible. |
|
Pricing and purchase options |
Avail yourself of customized purchase options to meet your exact research needs. Explore purchase options |
Global Dengue Testing Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, MIR has segmented the global dengue testing market based on product, service type, end use, and region.
-
Product Scope Outlook (Revenue, USD Million, 2018-2030)
-
ELISA-based Tests
-
Dengue IgG/IgM Detection Kits
-
RT-PCR Tests
-
Rapid Diagnostic Tests (RDTs)
-
NS1 Antigen Detection Kits
-
Lateral Flow Immunoassay
-
-
Service Type Outlook (Revenue, USD Million, 2018 - 2030)
-
Centralized Service
-
POC Service
-
-
End-use Outlook (Revenue, USD Million, 2018-2030)
-
Clinical Labs
-
HospitalsClinics
-
Home Healthcare
-
-
Regional Outlook (Revenue, USD Million, 2018 - 2030)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
Thailand
-
South Korea
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy